Clear cell renal cell carcinoma is the most common form of kidney cancer, affecting the tiny filters inside your kidneys that clean waste from your blood. While treatment depends on how far the disease has spread and your overall health, modern medicine offers a range of options from surgery to advanced drugs tested in research studies, giving patients more possibilities than ever before.

Understanding Your Treatment Path for Clear Cell Renal Cell Carcinoma

When you receive a diagnosis of clear cell renal cell carcinoma, the first question that often comes to mind is “what happens next?” The answer depends on several important factors. Your healthcare team will look at the size of the tumor, whether it has spread beyond the kidney, which stage the cancer is in, and your overall health condition. The main goals of treatment are to remove or destroy the cancer cells, prevent the disease from spreading or returning, manage any symptoms you might be experiencing, and help you maintain the best possible quality of life^[1].

Every person’s situation is unique, which is why your treatment plan will be tailored specifically to you. Some people are diagnosed when the tumor is still small and contained within the kidney, making it easier to treat. Others may discover their cancer when it has already grown larger or spread to nearby tissues or other parts of the body. Clear cell renal cell carcinoma gets its name from how the cells appear under a microscope—they look clear, like bubbles, because they contain a lot of lipids (fats) and glycogen^[2].

In the medical world, there are established treatments that doctors have used successfully for years, approved by medical societies and regulatory agencies. These are called standard treatments, and they form the backbone of kidney cancer care. At the same time, researchers around the world are constantly working to develop new and better therapies. These experimental treatments are tested in clinical trials, which are carefully designed research studies that help scientists understand whether a new drug or treatment approach is safe and effective. Participating in a clinical trial can give some patients access to cutting-edge therapies that aren’t yet available to the general public^[2].

Standard Treatment Approaches: What Doctors Use Today

Surgery remains the most important and effective treatment for clear cell renal cell carcinoma. When the cancer is caught early and hasn’t spread beyond the kidney, surgically removing the tumor offers the best chance of cure. The type of surgery your doctor recommends depends on the size and location of the tumor, as well as how well your other kidney is functioning^[2].

If your tumor is relatively small—typically less than 4 centimeters—your surgeon may be able to perform a partial nephrectomy. This means they remove only the cancerous part of the kidney along with a small amount of surrounding healthy tissue, leaving the rest of the kidney intact and functioning. This is particularly important if you only have one kidney, if your other kidney isn’t working well, or if you have other health conditions like diabetes or high blood pressure that affect kidney function. Preserving as much healthy kidney tissue as possible helps maintain your body’s ability to filter waste from your blood^[10].

For larger tumors, or when the cancer is located in the middle of the kidney where it’s difficult to remove just a portion, doctors often recommend a radical nephrectomy. This procedure involves removing the entire affected kidney, and sometimes nearby structures like lymph nodes, part of the tube connecting the kidney to the bladder (ureter), or the adrenal gland sitting on top of the kidney. The good news is that most people can live perfectly normal, healthy lives with just one kidney, as long as the remaining kidney is functioning properly^[2].

Modern surgical techniques have advanced significantly. Many nephrectomies can now be performed using minimally invasive methods such as laparoscopic surgery or robot-assisted surgery. These approaches use several small incisions instead of one large one, which typically means less pain after surgery, shorter hospital stays, faster recovery times, and smaller scars. Your surgeon will discuss which approach is best suited for your particular situation^[10].

For patients who cannot undergo surgery due to other medical conditions, or for those with small tumors who prefer a less invasive option, doctors may recommend ablation techniques. Thermal ablation uses heat to destroy cancer cells, while cryosurgery (also called cryoablation) freezes the tumor using extremely cold liquid nitrogen. These procedures are typically done by inserting a special needle or probe through the skin directly into the tumor, guided by imaging scans. While ablation can be effective for small tumors, long-term data shows that surgery still provides better outcomes for most patients^[2].

When clear cell renal cell carcinoma has spread beyond the kidney to other parts of the body—a situation called metastatic or stage IV disease—treatment becomes more complex. Surgery may still play a role, but it’s usually combined with systemic therapies, which are medications that travel through your bloodstream to reach cancer cells throughout your body^[9].

Targeted therapy drugs have revolutionized the treatment of advanced kidney cancer over the past two decades. These medications work differently from traditional chemotherapy. Instead of killing all rapidly dividing cells, targeted therapies attack specific molecules and pathways that kidney cancer cells need to grow and spread. Many of these drugs focus on blocking signals that tell the body to form new blood vessels that feed the tumor—a process called angiogenesis^[9].

Several targeted therapy drugs are approved for treating clear cell renal cell carcinoma. Sunitinib (brand name Sutent) and pazopanib are commonly used as first-line treatments for advanced disease. These drugs belong to a class called tyrosine kinase inhibitors or TKIs, and they work by blocking multiple proteins that cancer cells use to grow. Another drug in this category is cabozantinib (Cabometyx), which can be used both as an initial treatment and for patients whose cancer has progressed after other therapies. Axitinib (Inlyta) is another TKI often used in combination with other medications^[2][10].

Common side effects of targeted therapies include fatigue, diarrhea, changes in skin color or texture, high blood pressure, hand-foot syndrome (redness, swelling, and pain on the palms and soles), decreased appetite, and nausea. Most side effects can be managed with dose adjustments, supportive medications, or temporary breaks from treatment. Your healthcare team will monitor you closely and help you manage any side effects that arise^[9].

Immunotherapy has emerged as another powerful weapon against clear cell renal cell carcinoma. Unlike targeted therapies that attack cancer cells directly, immunotherapy helps your own immune system recognize and destroy cancer cells. Clear cell renal cell carcinoma is one of the cancers that responds particularly well to immunotherapy, which has given many patients longer survival and better quality of life^[2].

The most commonly used immunotherapies for kidney cancer are called checkpoint inhibitors. These drugs work by blocking proteins that prevent immune cells from attacking cancer. Nivolumab (Opdivo) and pembrolizumab (Keytruda) block a protein called PD-1, while ipilimumab (Yervoy) blocks a different checkpoint protein called CTLA-4. These drugs are often used in combination with each other or with targeted therapies. For example, nivolumab combined with ipilimumab, or pembrolizumab combined with axitinib, are approved combination regimens that have shown significant benefits in clinical trials^[9][12].

Side effects of immunotherapy are different from those of targeted therapy because they result from an overactive immune system. These can include fatigue, rash, itching, diarrhea, and more serious immune-related problems affecting the lungs, liver, intestines, hormone-producing glands, or other organs. While these side effects can be serious, doctors have become very experienced at recognizing and treating them early. Many patients tolerate immunotherapy well, and the benefits can be long-lasting, sometimes continuing even after treatment is stopped^[9].

Traditional chemotherapy doesn’t work well for clear cell renal cell carcinoma, which is why it’s rarely used. The biology of kidney cancer cells makes them resistant to most chemotherapy drugs. This is one reason why the development of targeted therapies and immunotherapy has been so important for kidney cancer patients^[3].

Radiation therapy, which uses high-energy beams to kill cancer cells, also has a limited role in treating the primary kidney tumor. However, it can be very effective for managing symptoms when cancer has spread to specific areas like the bones or brain. For example, if kidney cancer spreads to the spine and causes pain or threatens to damage the spinal cord, radiation can shrink the tumor and provide relief^[2].

The duration of treatment varies widely depending on your situation. If you have surgery to remove a localized tumor, the procedure itself might take a few hours, followed by several weeks of recovery. For advanced disease treated with targeted therapy or immunotherapy, you may take medications for months or even years, for as long as they’re working and the side effects are manageable. Your doctor will schedule regular scans and blood tests to monitor how well the treatment is working and watch for any signs that the cancer is growing or spreading^[9].

Innovative Treatments Being Tested in Clinical Trials

Research into new treatments for clear cell renal cell carcinoma is advancing rapidly. Scientists are constantly searching for more effective therapies with fewer side effects, and clinical trials are the pathway through which these promising new approaches move from the laboratory to patients. Understanding how clinical trials work can help you make informed decisions about whether participating in one might be right for you^[2].

Clinical trials progress through different phases. Phase I trials are the first studies in humans and primarily test whether a new treatment is safe, what dose should be used, and what side effects occur. These trials typically involve small numbers of patients. Phase II trials enroll more patients and focus on whether the treatment actually works—does it shrink tumors or slow cancer growth? Phase III trials are large studies comparing the new treatment to the current standard treatment to see if it’s better, equal, or not as good. Only treatments that succeed in phase III trials typically get approved by regulatory agencies for general use^[9].

One of the most exciting areas of research involves combining different types of immunotherapy drugs with targeted therapies in new ways. Studies are testing various combinations to see which pairings work best. For instance, researchers are investigating whether adding a drug called lenvatinib, which is a tyrosine kinase inhibitor, to pembrolizumab can improve outcomes. Early results from clinical trials have been promising, showing that some combinations can cause tumors to shrink in a high percentage of patients^[9][11].

Another promising drug being tested is belzutifan. This medication works in a unique way by targeting a protein called HIF-2 alpha, which is involved in how kidney cancer cells respond to low oxygen levels. Remember that genetic changes in the VHL gene are common in clear cell renal cell carcinoma—these changes cause HIF proteins to build up abnormally, which drives cancer growth. Belzutifan blocks HIF-2 alpha, essentially cutting off one of the cancer’s key growth signals. Clinical trials have shown encouraging results, and belzutifan is being tested both as a single drug and in combinations with other treatments^[11].

Researchers are also exploring adjuvant therapy—medication given after surgery to reduce the risk of cancer coming back. Traditionally, after surgical removal of localized kidney cancer, patients would simply be monitored with regular scans. But for patients at higher risk of recurrence, clinical trials are testing whether giving immunotherapy or targeted therapy after surgery can keep the cancer from returning. Some studies have shown that pembrolizumab given after surgery can extend the time before cancer comes back in high-risk patients^[11][13].

Novel approaches to activating the immune system are also under investigation. Scientists are studying cancer vaccines designed to train the immune system to recognize and attack kidney cancer cells. These aren’t prevention vaccines like those for infectious diseases, but rather treatment vaccines given to people who already have cancer. Some early-phase trials are testing personalized vaccines created specifically for each patient based on the unique mutations in their tumor^[9].

CAR T-cell therapy is another immunotherapy approach being adapted for kidney cancer. This technique involves removing immune cells from a patient’s blood, genetically engineering them in the laboratory to better recognize cancer cells, growing millions of these modified cells, and then infusing them back into the patient. CAR T-cell therapy has shown remarkable success in certain blood cancers, and researchers are working to make it effective for solid tumors like kidney cancer as well^[9].

Clinical trials for kidney cancer are happening at major cancer centers across the United States, Europe, and many other parts of the world. To be eligible for a trial, you typically need to meet specific criteria, which might include the stage of your cancer, whether you’ve had previous treatments, your overall health status, and the function of your remaining kidney. Your oncologist can help you search for appropriate trials, or you can explore databases like ClinicalTrials.gov, which lists studies recruiting patients. Some trials may provide the investigational treatment at no cost, though you may still have routine care expenses^[2].

One innovative area of research involves understanding the role of the tumor microenvironment—the normal cells, blood vessels, and immune cells that surround cancer cells. Scientists have discovered that these surrounding tissues can either help or hinder cancer growth. New drugs are being developed to modify the tumor microenvironment to make it less hospitable to cancer and more responsive to treatment^[9].

Researchers are also investigating biomarkers—measurable substances in the blood, urine, or tumor tissue that can predict how aggressive a cancer is or how well it will respond to specific treatments. For example, scientists are studying whether certain genetic mutations, protein levels, or immune cell patterns in tumors can identify which patients are most likely to benefit from immunotherapy versus targeted therapy. This kind of personalized medicine approach aims to match each patient with the treatment most likely to work for their particular cancer^[13].

Some trials are testing new drug delivery methods to get medication directly to the tumor while minimizing exposure to the rest of the body. Techniques under investigation include nanoparticles that carry drugs specifically to cancer cells, or medications that can be activated only at the tumor site. These approaches could potentially increase effectiveness while reducing side effects^[9].

Most common treatment methods

• Surgery
  • Partial nephrectomy removes only the tumor and a small margin of healthy kidney tissue, preserving kidney function
  • Radical nephrectomy removes the entire affected kidney, sometimes along with nearby lymph nodes or adrenal gland
  • Minimally invasive techniques including laparoscopic and robotic-assisted surgery offer faster recovery with smaller incisions
• Targeted Therapy
  • Sunitinib (Sutent) and pazopanib block proteins that help cancer cells grow and form new blood vessels
  • Cabozantinib (Cabometyx) targets multiple pathways cancer cells use for growth and spread
  • Axitinib (Inlyta) often used in combination with immunotherapy drugs
  • Sorafenib inhibits tumor cell growth and new blood vessel formation
• Immunotherapy
  • Nivolumab (Opdivo) and pembrolizumab (Keytruda) are checkpoint inhibitors that help the immune system attack cancer cells
  • Ipilimumab (Yervoy) blocks a different immune checkpoint, often combined with nivolumab
  • Combination immunotherapy approaches pairing checkpoint inhibitors with targeted therapies
• Ablation Techniques
  • Thermal ablation uses heat to destroy tumor cells through a probe inserted into the tumor
  • Cryosurgery freezes cancer cells using extremely cold liquid nitrogen
  • Typically used for small tumors in patients who cannot undergo surgery
• Radiation Therapy
  • High-energy beams target cancer cells that have spread to bones, brain, or other organs
  • Primarily used for symptom relief and management of metastatic disease
  • Can help control pain and prevent complications from cancer spread